Skip to main content

Month: July 2021

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.Conference Call Details:  Date: Tuesday, August 10, 2021Time: 4:45 p.m. Eastern timeParticipant Dial-in: 1-833-953-2434 (U.S.)1-412-317-5763 (International)Replay Dial-in (Passcode 10157937):(telephonic replay through August 17, 2021) 1-877-344-7529 (U.S.)1-412-317-0088...

Continue reading

Northrop Grumman to Participate in Jefferies Industrials Conference

FALLS CHURCH, Va., July 26, 2021 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) will participate in the Jefferies Industrials Conference on Wednesday, August 4. Dave Keffer, corporate vice president and chief financial officer, will present beginning at 9:00 a.m. Eastern time. The presentation will be webcast live at http://investor.northropgrumman.com. Northrop Grumman solves the toughest problems in space, aeronautics, defense and cyberspace to meet the ever evolving needs of our customers worldwide. Our 90,000 employees define possible every day using science, technology and engineering to create and deliver advanced systems, products and services. Note: Statements to be made at the conference, including in the presentation and in any accompanying materials, contain or may contain statements that constitute “forward-looking...

Continue reading

Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer

Bruce E. EatonEditas Medicine announced Bruce E. Eaton, Ph.D., has been promoted to Executive Vice President and Chief Business Officer.Dr. Eaton joined the Company in 2018 and brings more than 30 years of experience to the role CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that Bruce E. Eaton, Ph.D., has been promoted to Executive Vice President and Chief Business Officer. In his new role, Dr. Eaton oversees the Company’s corporate strategy, business development, and alliance management. “I am thrilled to announce the promotion of Bruce to Executive Vice President and Chief Business Officer. Bruce has been a vital member of our team for many years, driving performance and demonstrating extraordinary leadership. With his...

Continue reading

Get back to school with tech from Verizon

5G phones, accessories and great deals – Verizon has it all for connected learning BASKING RIDGE, N.J., July 26, 2021 (GLOBE NEWSWIRE) — New school year. New tech. Verizon is ready to help you move forward as you head back to school, however that may look this year. We have the latest iPhones, iPads, accessories and more. Whether you’re in-person, virtual or a hybrid of the two, you can feel confident knowing Verizon can help keep you connected on the 5G network more people rely on, with the latest tech and coolest accessories available. Teachers and college students can get our best pricing, always.Teachers and college students get our best price on Unlimited plans, all year long. Teachers get $30 per line per month with four lines on Start Unlimited plan with Auto Pay (plus taxes and fees).1 College students get two lines...

Continue reading

Usio Reports Record Second Quarter Electronic Payments Transaction and Processing Volume

Total Dollars processed in the second quarter of 2021 a record $2.73 billion, up 47% sequentially from previous record first quarter SAN ANTONIO, July 26, 2021 (GLOBE NEWSWIRE) — Usio, Inc. (Nasdaq: USIO), an integrated electronic payment solutions provider, today reported record transactions and processing volume for the second quarter of 2021. Louis Hoch, President and Chief Executive Officer of Usio, said, “This is our third consecutive quarter of record electronic payments and dollar transaction processing volume. ACH electronic check dollars processed almost quadrupled this quarter, while electronic check transactions, return check transactions and card transactions processed all doubled, at least. These results illustrate that we are on a rapid growth trajectory. Our success is built on our strategy to invest in our high...

Continue reading

EMCORE Corporation to Host Fiscal 2021 Third Quarter Conference Call on August 5, 2021

ALHAMBRA, CA, July 26, 2021 (GLOBE NEWSWIRE) — EMCORE Corporation (Nasdaq: EMKR), a leading provider of advanced mixed-signal products that serve the aerospace & defense and broadband communications markets, will announce its fiscal 2021 third quarter results for the period ended June 30, 2021 on Wednesday, August 4, 2021 after the market close. Conference Call Information The Company will host a conference call to discuss these results at 8:00 a.m. ET (5:00 a.m. PT) on Thursday, August 5, 2021. President & Chief Executive Officer, Jeff Rittichier and Chief Financial Officer, Tom Minichiello will provide an overview of the results, discuss current business conditions, and conduct a question and answer session. The call will be available, live, to interested parties by dialing 800-353-6461. For international callers, please...

Continue reading

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial” in the Journal of Pain Research. The article is available online at the journal website. The article reports an intention-to-treat analysis of a double-blind, randomized, sham-controlled trial that compared 3-months of at-home treatment with a standard (active) or low dose (sham) Quell device in 119 subjects with fibromyalgia. Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). About Fibromyalgia Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances....

Continue reading

eXp Realty Exceeds 60,000 Real Estate Agents Globally

Milestone Represents 85% Year-over-year Agent GrowtheXp Realty reaches 60k Agents WorldwideToday eXp Realty reaches 60k Agents WorldwideBELLINGHAM, Wash., July 26, 2021 (GLOBE NEWSWIRE) — eXp World Holdings, Inc. (Nasdaq: EXPI), the holding company for eXp Realty, one of the fastest-growing residential and commercial real estate companies in the world, today announced it has exceeded 60,000 agents globally. This represents a year-over-year increase of 85% when compared to 32,403 agents in July 2020. “Our growth is a direct result of our agent-centric value proposition and our commitment to providing the best possible resources for our agents to succeed,” said Jason Gesing, CEO of eXp Realty. “Agents are immersed in our innovative, cloud-based model that provides clear financial incentives and unrivaled technology...

Continue reading

Willis Towers Watson Increases Share Repurchase Program by $1 Billion; Announces Investor Day in September

ARLINGTON, Va. and LONDON, July 26, 2021 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ:WLTW), a leading global advisory, broking and solutions company, announced that its Board of Directors approved an increase of $1 billion to its existing share repurchase program, which has approximately $500 million remaining on the current open-ended repurchase authority. Willis Towers Watson is authorized to repurchase shares, by way of redemption, and will consider whether to do so from time to time, based on many factors, including market and economic conditions, applicable legal requirements and other business considerations. Willis Towers Watson anticipates utilizing this authorization in 2021 and 2022. The share repurchase program has no termination date and may be suspended or discontinued at any time. Willis Towers Watson also expects...

Continue reading

Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders

IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) —  Odyssey Group International, Inc. (OTCQB: ODYY) (“ODYY” or “the Company”), Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it plans to hold the Annual Meeting of Stockholders of Odyssey Group International, Inc. in September, 2021. In order to be considered at the annual meeting, any and all stockholder proposals must be received at the principal executive offices of the Company, 2372 Morse Ave, Irvine, CA 92614, c/o the Corporate Secretary, on or before the close of business on Thursday, August 5, 2021, and must be in compliance with the procedures regarding stockholder proposals set forth...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.